Innate Pharma highlights ANKET® abstracts selected for the EHA 2025 congress
Innate Pharma reports first quarter 2025 business update and financial results
Innate Pharma highlights preclinical anti-tumor efficacy data of its antibody drug conjugate IPH4502 at the AACR 2025 annual meeting
Innate Pharma regains its rights on CD123 targeting ANKET® and announces Sanofi’s intention to make a strategic investment in the Company
Innate Pharma reports full year 2024 financial results and business update
Innate Pharma highlights antibody drug conjugate IPH4502 abstract selected for the AACR 2025 annual meeting
Innate Pharma announces first patient dosed in Phase 1 study of its Nectin-4 targeting antibody drug conjugate IPH4502 in selected advanced solid tumors
Innate Pharma presents lacutamab improved health-related quality of life data at ASH 2024 from TELLOMAK Phase 2 study in patients with cutaneous T cell lymphoma
Innate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) announce up to $7.9m investment from IFLI to support IPH6501 development in Follicular Lymphoma
Innate Pharma highlights abstracts selected for the ASH annual meeting 2024
